Drugs/Recall·openFDA/drug

ACCORD HEALTHCARE, INC. — Class II: Levothyroxine Sodium Tablets, USP, 50 mcg (0.05 mg), 1000-count bottles, Rx Only, Manufact

MediumPublished Sep 2, 2026· AI-analyzed Sep 7, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Accord Healthcare, Inc. has initiated a Class II recall for Levothyroxine Sodium Tablets, USP, 50 mcg (1000-count bottles) due to the product being identified as a subpotent drug. The recall is currently classified as ongoing.

Who it affects

This recall affects Accord Healthcare, Inc., Intas Pharmaceuticals Limited, and pharmacy distributors or healthcare facilities utilizing the 1000-count bulk bottles of 50 mcg Levothyroxine Sodium.

Why it matters

A Class II recall for subpotency suggests a failure to meet USP specifications, which may stem from manufacturing deviations or stability issues. For a narrow therapeutic index drug like levothyroxine, subpotency can lead to clinical under-treatment. Regulatory teams may expect increased scrutiny regarding the manufacturer's stability testing programs and process controls.

Practical takeaway

Quality units should verify if affected lot numbers of Levothyroxine Sodium (NDC 16729-448-17) are in inventory and initiate quarantine procedures. Regulatory and QA teams should review stability data for similar product lines to ensure continued potency throughout the shelf life.

FDA source material

Class II. Reason: Subpotent Drug. Product: Levothyroxine Sodium Tablets, USP, 50 mcg (0.05 mg), 1000-count bottles, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-448-17.. Firm: ACCORD HEALTHCARE, INC. (Raleigh NC United States). Status: Ongoing.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.